No medication currently exists that reliably restores normal esophageal peristalsis in people with ineffective esophageal motility (IEM), so treatment focuses on managing symptoms and controlling concurrent acid reflux rather than fixing the underlying muscle weakness. A handful of serotonergic drugs show promise on manometry readings, and newer research on breathing exercises and surgical devices adds to the toolkit, but the honest picture is that IEM management remains a patchwork of partial solutions rather than a single definitive therapy.
What IEM Actually Means for Treatment Planning
IEM is diagnosed when the esophagus fails to generate strong enough contractions to move food and liquid efficiently from throat to stomach. Under current diagnostic criteria, more than 70 percent of test swallows need to be ineffective, or at least half must be outright failed swallows, for a firm diagnosis. When results fall between 50 and 70 percent ineffective swallows, the diagnosis is considered inconclusive and clinicians look for additional evidence like abnormal bolus clearance on imaging.
That grading matters for treatment because not every person who meets the criteria is equally affected. Severe IEM, with more than 70 percent ineffective swallows, correlates with a heavier acid reflux burden, especially when lying down. Milder forms tend not to worsen over time and may not consistently reduce quality of life. This means a clinician’s first job is deciding how aggressively to treat: someone with occasional mild dysphagia and borderline manometry results needs a very different plan than someone with severe reflux damage and near-absent peristalsis.
Acid Suppression with PPIs
Because IEM and gastroesophageal reflux disease (GERD) frequently coexist, proton pump inhibitors (PPIs) are often among the first medications prescribed. They reduce acid production and can heal esophageal inflammation, but they don’t actually improve the motility problem itself. A systematic review of studies examining manometric outcomes in IEM patients treated with PPIs found that healing esophagitis did not lead to significant improvement in esophageal motility parameters.1PubMed Central. Outcomes after treatment with proton pump inhibitors in patients with ineffective esophageal motility: a systematic review
That finding highlights a common misconception: many people assume that if acid reflux is causing their swallowing trouble, then eliminating the acid should fix everything. In reality, motility abnormalities grow more prevalent as reflux disease gets more severe, from non-erosive reflux through erosive disease and into Barrett’s esophagus.2PubMed Central. Esophageal motility abnormalities in gastroesophageal reflux disease Acid suppression can break the cycle of inflammation and prevent further damage, which makes it a worthwhile part of the strategy. But it rarely reverses the muscle weakness that defines IEM.
Prokinetic and Serotonergic Medications
Prokinetics are the class of drugs most intuitively suited to IEM, since they aim to boost smooth muscle contractions in the gut. In practice, the results have been underwhelming. The beneficial effects are limited and confined to specific drugs, and the impact on actual symptoms, as opposed to manometry numbers, remains unclear.3PubMed Central. Management of Ineffective Esophageal Hypomotility Researchers at a 2018 Stanford symposium on IEM concluded bluntly that no effective pharmacotherapy exists and that prokinetic agents specifically targeting esophageal smooth muscle still need to be developed.4PubMed Central. Ineffective esophageal motility: Concepts, future directions, and conclusions from the Stanford 2018 symposium
Among the drugs that have shown at least some measurable effect on esophageal motility parameters, three stand out: buspirone, mosapride, and prucalopride. All work through serotonin receptor pathways that influence esophageal smooth muscle. Of these, buspirone has the most evidence and the most interesting clinical profile because it’s already widely available as an anti-anxiety medication, making off-label use relatively accessible.
Buspirone
Buspirone acts on serotonin receptors in a way that boosts both the strength and duration of esophageal contractions. In healthy volunteers, a single dose roughly doubled contraction amplitude and increased lower esophageal sphincter resting pressure.5PubMed. Effect of buspirone, a 5-HT1A receptor agonist, on esophageal motility in healthy volunteers Those are encouraging numbers on paper, but they come from people whose esophagus already worked normally. The question is whether the drug can meaningfully improve function in people with genuinely impaired motility.
Early evidence suggests it can help, at least in certain populations. In patients with systemic sclerosis, a connective tissue disease that commonly causes severe esophageal dysfunction, buspirone showed a beneficial effect on lower esophageal sphincter pressure and has been called a “putative therapeutic option” for this group.6PubMed Central. Evaluation and management of esophageal manifestations in systemic sclerosis Previous research has also suggested it enhances esophageal peristalsis and sphincter function more broadly.7PubMed Central. Buspirone, a new drug for the management of patients with ineffective esophageal motility?
The catch is the gap between improved manometry numbers and improved patient experience. A drug can make contractions measurably stronger without making someone feel noticeably better at swallowing. Large, long-term trials proving that buspirone reduces dysphagia and reflux symptoms in IEM patients are still lacking. For now, it’s a reasonable trial in patients with significant symptoms, especially if other options have failed, but expectations should be tempered.
Other Serotonergic Agents
Mosapride and prucalopride work through different serotonin receptor subtypes and have similarly shown improvements in motility parameters without clear evidence of symptom benefit. Mosapride is not available in many countries, including the United States. Prucalopride is approved for chronic constipation and sometimes used off-label for upper gastrointestinal motility problems. Neither has strong enough evidence in IEM specifically to be considered a standard therapy, and clinicians who prescribe them for this condition are venturing into relatively uncharted territory.
Diaphragmatic Breathing Training
One of the more surprising recent findings in IEM management involves no drugs or devices at all. Diaphragmatic breathing training (DBT), a structured exercise program that strengthens the crural diaphragm surrounding the lower esophageal sphincter, appears to improve both sphincter pressure and esophageal contractility. In a study of patients with reflux symptoms, the prevalence of IEM dropped from about 38 percent to 29 percent after a course of breathing training, and average esophageal contraction strength increased significantly.8PubMed. Effect of Diaphragmatic Breathing Training on the Esophagogastric Junction and Esophageal Motility in Patients With Reflux Symptoms Lower esophageal sphincter pressure also rose, from an average of about 26 mmHg to 29 mmHg, even in patients who started with a weak sphincter.
This is notable because diaphragmatic breathing is free, carries no side effects, and can be done at home. Earlier research on diaphragm biofeedback training in GERD patients had already shown improvements in the mechanical barrier at the gastroesophageal junction when combined with acid-suppressing medication.9Diseases of the Esophagus. Short-term and long-term effect of diaphragm biofeedback training in gastroesophageal reflux disease: an open-label, pilot, randomized trial The newer study adds the intriguing finding that the contractions within the esophagus itself got stronger, not just the sphincter at the bottom.
The limitation is that these are relatively small studies, and the breathing exercises need to be practiced consistently to maintain the benefit. For someone with mild-to-moderate IEM who is looking for a non-pharmacological approach, though, this is one of the few interventions with measurable manometric improvement backed by published data.
Surgical and Device-Based Options
Surgery enters the IEM conversation primarily when a patient also has significant GERD that isn’t controlled by medication. The traditional concern has been that fundoplication, the standard anti-reflux surgery where the top of the stomach is wrapped around the lower esophagus, could worsen swallowing difficulties in someone whose esophagus already struggles to push food through. The logic seems sound: if contractions are already weak, adding mechanical resistance at the bottom would just create a traffic jam.
Recent evidence suggests that fear is somewhat overblown. A study tracking IEM patients who underwent total fundoplication found that only about 16 percent experienced dysphagia afterward, and no patient required reoperation for it. Among those who had dysphagia before surgery, most actually saw it resolve.10PubMed. Ineffective esophageal motility is not a contraindication to total fundoplication These results have pushed many surgeons away from the blanket rule that IEM patients should only get a partial wrap or no surgery at all.
Magnetic sphincter augmentation (MSA), a newer device-based approach where a ring of magnetic beads is placed around the lower esophageal sphincter, adds another dimension. The beads hold the sphincter closed against reflux but separate easily when a swallowed bolus pushes through. In a review of post-implantation outcomes, about a third of patients who had IEM before the procedure reverted to a normal motility pattern afterward, and post-operative dysphagia was linked to pre-existing dysphagia rather than to the manometric diagnosis of IEM.11Magnetic Medicine. Magnetic surgery for lower esophageal sphincter augmentation: two decades of research and innovation The fact that motility sometimes normalizes after MSA suggests that in some patients, the weak contractions may have been a consequence of chronic reflux damage rather than an independent problem.
When IEM Is Secondary to Another Disease
IEM doesn’t always appear in isolation. In systemic sclerosis, an autoimmune condition that causes fibrosis in connective tissues, the esophagus is one of the most commonly affected organs. Esophageal involvement in these patients can be severe, progressive, and poorly responsive to standard reflux treatments.12PubMed Central. Esophageal Dysfunction in Systemic Sclerosis: An Update Current strategies focus on controlling reflux and attempting to improve peristalsis, but there’s no established treatment that halts disease progression in the esophagus itself.
Other conditions associated with secondary IEM include diabetes with autonomic neuropathy, hypothyroidism, and certain neuromuscular disorders. The treatment approach in these cases is dual: manage the motility symptoms with the tools described above while addressing the underlying systemic disease. Someone whose IEM is driven by poorly controlled diabetes, for example, may see modest improvement in esophageal function as their metabolic control improves, whereas someone with progressive systemic sclerosis may not.
Diagnostic Tools That Shape Treatment Decisions
Treatment planning for IEM depends heavily on what the diagnostic workup reveals, and newer tools are changing the picture. High-resolution manometry remains the standard for diagnosing IEM, using the criteria mentioned earlier to quantify contraction strength and the percentage of failed swallows.13PubMed. Chicago Classification update (V4.0): Technical review on diagnostic criteria for ineffective esophageal motility and absent contractility
A newer tool called the functional lumen imaging probe (FLIP) adds a different layer of information by measuring how the esophagus distends and contracts in response to a balloon inflated inside it. In a clinical practice study, among patients diagnosed with IEM or no motility disorder on standard manometry, nearly half showed sustained contractions on FLIP that raised concern for a spastic-type process along the achalasia spectrum.14Diseases of the Esophagus. The broad impact of functional lumen imaging probe panometry in addition to high-resolution manometry in an esophageal clinical practice In plain language, some people who look like they have weak contractions on one test actually have a different kind of motility disorder when tested another way. That distinction matters because the treatment for achalasia-spectrum disorders is entirely different from IEM management and can be quite effective.
If you’ve been told you have IEM and your symptoms are particularly severe or your treatment isn’t working, it’s worth asking whether FLIP testing has been considered. It’s not universally available, but it can sometimes uncover a treatable condition hiding behind an IEM diagnosis.
Long-Term Outlook
One reassuring aspect of IEM is that for many patients, the condition doesn’t steadily worsen. Research tracking patients over time found that about 42 percent still had dysphagia at follow-up, but patients whose motility normalized on solid-bolus swallows reported significantly less difficulty swallowing.15PubMed Central. Long-term Prognosis and Prognostic Factors in Ineffective Esophageal Motility Chest pain and reflux symptoms didn’t correlate as clearly with motility normalization, suggesting those complaints may have separate contributing factors.
The Stanford symposium conclusions align with this: milder variants of IEM don’t consistently progress or degrade quality of life over time.4PubMed Central. Ineffective esophageal motility: Concepts, future directions, and conclusions from the Stanford 2018 symposium For patients with borderline or mild IEM, watchful waiting combined with lifestyle measures and acid suppression when needed is a perfectly reasonable approach, not a sign that something is being missed.
IEM in Older Adults
Esophageal motility disorders become more common with age. A large international multicenter study found that the prevalence of any motility disorder rose from about 46 percent in patients under 65 to 56 percent in those 75 and older, and dysphagia was the most common reason for testing in the oldest group.16PubMed Central. Esophageal motility disorders among elderly patients: An international multicenter study Older patients were also more likely to have specific disorders like achalasia and hypercontractile esophagus rather than isolated IEM.
For older adults with IEM, the treatment principles are the same but the practical considerations shift. Polypharmacy is common in this age group, and several medication classes can impair esophageal motility. Anticholinergic drugs, which are found in many allergy, bladder, and sleep medications, are among the most concerning. Selective serotonin reuptake inhibitors, estrogen, and cannabis have also been flagged as needing further study for their potential effects on esophageal function.17Foregut: The Journal of the American Foregut Society. The Impact of Medications on Esophageal Motility If you’re an older adult with IEM symptoms, a careful medication review is a logical first step before adding new treatments.
Acupuncture and Complementary Approaches
Acupuncture isn’t the first thing most gastroenterologists would recommend for IEM, but a randomized trial in Chinese patients with refractory GERD symptoms produced some striking manometric changes. After acupuncture treatment, the number of ineffective contractions dropped from 43 to 18, fragmented contractions fell from 36 to 12, and the percentage of intact contractions rose significantly. Average contraction strength also improved.18PubMed Central. Acupuncture Improved the Function of the Lower Esophageal Sphincter and Esophageal Motility in Chinese Patients with Refractory Gastroesophageal Reflux Disease Symptoms: A Randomized Trial
These results are interesting but should be interpreted cautiously. The study was conducted in a single center, acupuncture protocols are difficult to standardize across practitioners, and the placebo challenge in acupuncture research is well-known. Still, for patients who have exhausted conventional options and are looking for something else to try, the data at least suggests this isn’t a completely baseless direction. The biological plausibility is there: acupuncture affects autonomic nervous system activity, which in turn influences smooth muscle function throughout the gastrointestinal tract.
Practical Lifestyle Measures
While none of the lifestyle strategies for IEM have undergone rigorous clinical trials the way medications and devices have, gastroenterologists routinely recommend several behavioral adjustments that follow logically from how the condition works:
- Eating posture and timing: Staying upright during and for at least 30 minutes after meals lets gravity assist transit, partially compensating for weak peristalsis. Eating the last meal of the day well before bedtime reduces supine reflux exposure, which is particularly high in severe IEM.
- Meal texture and size: Smaller, more frequent meals reduce the volume the esophagus needs to clear in any single episode. Some patients find that foods with moderate moisture and softer textures are easier to move through, while very dry or sticky foods are more likely to lodge.
- Liquid chasers: Sipping water between bites can help wash food through the esophagus when peristaltic pressure alone isn’t sufficient. This is simple but genuinely effective for many people with mild dysphagia.
- Reflux triggers: Avoiding known reflux-provoking foods and drinks (acidic, fatty, caffeinated, or alcoholic) reduces acid exposure in a system that already clears acid slowly due to weak contractions.
These measures sound basic, and they are. But given the limited pharmacological options, they form a meaningful part of day-to-day management for most IEM patients and can make a real difference in symptom burden.
Medications That Can Make IEM Worse
An underappreciated aspect of IEM management is avoiding drugs that suppress esophageal motility. If you already have borderline peristalsis and then start a medication that weakens smooth muscle contractions, you can tip from asymptomatic into troublesome dysphagia. Anticholinergic medications are the most common culprits, and they’re found in a surprising number of over-the-counter and prescription products, from diphenhydramine (a common sleep aid and antihistamine) to certain bladder medications and older antidepressants. Calcium channel blockers, nitrates, and opioids also reduce esophageal contractility. Any of these can push someone with subclinical IEM into symptomatic territory, or make already-diagnosed IEM harder to manage. A conversation with your prescriber about whether any of your medications could be contributing to the problem is a low-effort, high-value step that sometimes leads to meaningful improvement without adding anything new to the treatment regimen.